TL;DR: Cannabis equities hold Thursday gains into Friday afternoon, with the MSOS ETF testing resistance as Q2 earnings season enters its final stretch. Multi-state operators consolidate recent advances while investors await remaining reporters including Trulieve and Verano. Schedule III rescheduling remains an asymmetric catalyst with no confirmed DEA timeline.
Market Analysis
Cannabis equities carried Thursday constructive session into Friday morning, with the MSOS ETF holding the upper band of its recent consolidation range as afternoon trade begins. Green Thumb Industries (GTBIF) and Curaleaf Holdings (CURLF) maintained their positions after a week that produced mixed fundamental signals across the broader cannabis equity universe.
Volume patterns across cannabis names indicate measured institutional positioning ahead of the final Q2 earnings releases scheduled through late July. Trulieve Cannabis (TCNNF) and Verano Holdings (VRNOF) remain among the most closely watched reporters yet to announce, with both companies having guided toward positive adjusted EBITDA for Q2 despite persistent headwinds: high-interest-rate financing costs, state-level excise tax pressure, and the continued absence of federal rescheduling implementation.
The cannabis tracking universe reflects mixed technical signals heading into Friday close. Several MSOs are trading near 20-day moving average support zones. Canadian LP names including OGI Group (OGI) and Tilray Brands (TLRY) face ongoing pressure from domestic oversupply dynamics, though TLRY international pharmaceutical cannabis segment provides partial insulation from North American pricing headwinds. Cresco Labs (CRLBF) and AYR Wellness (AYRWF) are trading in line with sector averages after each reported earlier in the Q2 cycle.
Regulatory and Market Context
The DEA Schedule III rescheduling proceeding remains in administrative review with no confirmed ruling date as of mid-July 2026. The timeline has extended beyond initial projections. The administrative process including public comment periods and potential legal challenges from anti-legalization groups creates inherent schedule uncertainty. However, the option value embedded in rescheduling continues to underpin institutional interest in MSOs with positive EBITDA trajectories, as the primary near-term benefit would be relief from IRC Section 280E federal tax treatment.
State-level developments offer incremental near-term catalysts. Ohio adult-use market continues its ramp, providing a revenue lift for operators including Green Thumb Industries and Verano with existing Ohio medical dispensary footprints. Pennsylvania adult-use legislation remains in legislative limbo but has gained renewed political momentum heading into the second half of 2026. Florida, the largest single-state MSO revenue market, provides continued regulatory stability for operators including Trulieve and Verano MUV brand following the 2024 Amendment 3 defeat.
Earnings quality metrics will be the primary Friday afternoon data point for institutional analysts. Q2 reports from remaining reporters will be analyzed for same-store sales trends, gross margin progression, SGA discipline, and adjusted EBITDA conversion. These four metrics are most consistently correlated with MSO equity performance in the current cycle.
Conclusion
Friday afternoon positioning in cannabis equities reflects a sector stabilized after extended base-building, with the Q2 earnings final stretch representing the next significant fundamental catalyst. Investors and traders should monitor both earnings surprise potential from remaining reporters and any DEA administrative updates that could accelerate Schedule III implementation timelines. Use the cannabis stock tracker to monitor real-time price movements across the full MSO and LP universe heading into the weekend close.